Multifunctional DNA nanomaterials: a new frontier in rheumatoid arthritis diagnosis and treatment
- 16 December 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (9) , 4974-4999
Abstract
DNA nanomaterials offer promising advancements in addressing the challenges of rheumatoid arthritis (RA) through targeted drug delivery, biomarker detection, and therapeutic innovation.Keywords
Funding Information
- National Natural Science Foundation of China (82101077)
- National Natural Science Foundation of China (82201131)
- Sichuan University (RCDWJS2023-5)
- Fundamental Research Funds for the Central Universities
- China Postdoctoral Science Foundation (2023T160455)
- China Postdoctoral Science Foundation (2021M692271)
This publication has 140 references indexed in Scilit:
- Tetrahedral Framework Nucleic Acid Loaded miR‐23b Inhibits Synovial Inflammation and Cartilage Matrix Degradation in the Treatment of Rheumatoid ArthritisAdvanced Functional Materials, 2023
- An interdigitated aptasensor to detect interleukin-6 for diagnosing rheumatoid arthritis in serumBiotechnology and Applied Biochemistry, 2021
- Functionalizing Framework Nucleic‐Acid‐Based Nanostructures for Biomedical ApplicationAdvanced Materials, 2021
- What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis‐Based Approaches to Its Prediction?ACR Open Rheumatology, 2021
- Challenges and Perspectives of DNA Nanostructures in BiomedicineAngewandte Chemie International Edition, 2020
- The Lung in Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Single‐Particle Tracking and Modulation of Cell Entry Pathways of a Tetrahedral DNA Nanostructure in Live CellsAngewandte Chemie International Edition, 2014
- Inhibition of Connective Tissue Growth Factor Ameliorates Disease in a Murine Model of Rheumatoid ArthritisArthritis & Rheumatism, 2013
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseasesArthritis & Rheumatism, 1971